The fraction of viable cells was determined on cells in culture using a luminescence based assay (CellTiter-Glo, Promega, Madison, WI, USA). Ren-01 and Ren-02 human RCC cells were plated in 96-well plates (10 000 cells/0.2 ml DMEM medium), allowed to adhere, and compounds (both from Pfizer, New York, NY, USA) were added. After 48 h, viability was determined using a multi-label counter (Victor2 1420 Wallac, Perkin-Elmer, Waltham, MA, USA). Chou-Talalay analysis was used to determine whether combination drug effects were antagonistic, additive or synergistic (Chou and Talalay, 1984).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.